Abstract
Treating dyslipidaemia lowers the risk of coronary artery disease (CAD). Although statins stand as the first line agents used for CAD prevention, patients may not reach their recommended goals or they discontinue treatment due to adverse effects. Camel milk has been postulated to have an effect on dyslipidaemia. A single blind, randomised clinical trial was conducted with the aim of investigating the anti-dyslipidaemic effect of camel milk in patients with untreated dyslipidaemia. Study participants were recruited from the Family Medicine Clinics of the King Saud Medical City, Riyadh, Saudi Arabia. Blood levels of low density lipoprotein-cholesterol and total cholesterol dropped following three months of treatment with both statins and camel milk. The effects in both treatment groups were statistically equivalent. The results demonstrate that camel milk could be an alternative intervention to statin therapy for dyslipidaemia under some circumstances; however, further studies are needed to understand its efficacy. (c) 2018 Elsevier Ltd. All rights reserved.